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As the corresponding author, I confirm that this manuscript has been read and 
approved for submission by all the named authors. 
 
Yours sincerely 
Dr Manoj Sivan MD FRCP Ed 
Corresponding author 
Cover letter
***Reviews for Manuscript and author responses 
 
Reviewer #1: Second review of "Experimental placebo analgesia is equivalent and reproducible in 
individuals with chronic pain when compared to healthy individuals" ms number: PAIN-D-19-
01035R1 
 
The revision has significantly improved the manuscript. This is a study with several strong points, 
especially that it is very well controlled, and that investigates a theoretically and clinically important 
problem. However, there are still some problems with the manuscript. 
Author response: We thank the reviewer for their detailed feedback and have made appropriate 
updates as summarised below. 
 
The English language in the text is much improved, but should still be looked over and corrected by a 
native English speaker. 
 
Author response: We have reviewed the manuscript throughout and updated the language for 
clarity where needed. 
 
Abstract, l. 40: why is the placebo effect a "meaningful" reduction in pain? A clinically significant 
reduction in pain, if that is what is meant, has in at least two studies been shown to be 1.3 units on a 
scale similar to the one used here, which is more than the placebo effect reported in this ms. I 
suggest to delete "meaningful". 
Author response: We have removed the term “meaningful” as per the reviewer’s suggestion. 
 
Design: sessions 1 and 2 should be included along with the other within-subject factors. 
Author response: This detail has been added to the Design section (P5, Line 9). 
 
Laser stimuli: Pain threshold and intensity can vary between the arms. Were the laser stimuli 
calibrated individually for each arm? This must be described more precisely. 
Author response: This detail has been added to the Laser Stimuli section (P6, Line 5). 
 
Reproducibility: I assume that the participants were in the same groups (control, placebo) in session 
2 as they were in session 1, and this should be explicitly stated. 
Author response: We have updated the manuscript with this detail as suggested (P9, Line 20). 
 
Please be more specific on what the dressing is that covered the placebo cream? 
Author response: More detail of the dressing has been added to the Conditioning Phase (Phase 2) 
section (P7, Line 20) 
 
How long was the interval from the end of the conditioning phase till the start of the post-
conditioning phase? In the studies known to me, the placebo treatment has been re-applied in this 
interval. Why was the cream not re-applied before the post-conditioning phase? 
Response to Reviewers
Author response: The post-phase was almost immediately after the conditioning phase. We have 
updated the manuscript with this detail in the Conditioning Phase section (P8, Line 20). 
 
P. 9, l. 3: unconscious conditioning is referred to. How many of the participants had used pain-
relieving cream previously? 
Author response: We did not make a record of participants’ previous use of analgesic creams, 
although this would have been useful data in retrospect. Our assumption is that unconscious 
conditioning could have potentially occurred, based on the experimental design rather than 
considerations of the participants’ prior experience. We have updated the manuscript text here to 
clarify that unconscious conditioning could occur “due to the participants’ experience of 
experimental pain reduction. (P9, Line16)” 
 
Results, Placebo effect: the placebo effect was 0.74 points on an 11-point scale, and is described as 
"strong". Why is 0.74 a strong effect? Please provide the effect size, or compare to other studies 
(several studies have shown larger effects). 
Author response: Unfortunately there are no widely accepted standardised effect size metrics (e.g. 
equivalent to Cohen’s d or eta-squared) from linear mixed models and we cannot therefore use such 
metrics to compare to other studies. In addition, studies from other groups may not have used the 
pain scale in the same way (with the same anchors) used in this study. A more comprehensive 
comparison to other studies (e.g. based on meta-analysis of effect sizes) is beyond the scope of the 
current article and so we have removed the word “strong” to prevent confusion (P 13 Line 7 and P14 
line 3). 
 
Results, treatment x phase x arm interaction: it is stated that the 3-way interaction "modified the 
pain rating…by 0.26 points" (the beta value in table 3) compared to the treatment x phase 
interaction. I am not familiar with mixed models, but I do not understand this statement: I guess that 
pain ratings were modified by adding a third factor, arm, but how was pain modified? Increased or 
decreased? And where? Mean overall pain is of course the same whether you have two or three 
factors. And why is the beta-value of 0.26 mixed into this? My understanding of a beta value is not 
that it is directly translated into changes in a dependent variable (pain intensity). 
Author response: We have added the following explanation to the supplementary materials to 
enable the reader to interpret the beta coefficients (we have also updated the Table 3 legend to 
summarise these points): “Coefficients in fixed effects models are interpreted in the same way as in 
ordinary least squares regressions. For the categorical predictors, the model generates dummy 
variables for the observed categorical predictors, one of which is used as the base/reference 
category. The regression coefficient is the partial slope of the linear relationship between the 
outcome variable (pain rating) and the part of a predictor variable that is independent of 
(uncorrelated with) all other predictor variables. The magnitude of the beta represents the change in 
pain rating associated with a change of value 1 in the predictor variable when all other predictor 
variables are held constant. Since we are dealing with the interpretation of the beta coefficients 
from categorical variables, and the betas reported are unstandardized (i.e. not adjusted according to 
the standard deviation of the variables), the betas have a meaningful interpretation in terms of the 
original pain scale.” (Supplementary Materials). 
To further elaborate for the reviewer with some examples: The intercept of the model (value of 
6.08) is the value we would predict for the pain rating if all other coefficients (betas) were zero. 
Categorical predictor variables, for example “treat” in Table 3, are dummy coded such that the levels 
change by one unit (for two levels, these values are 0 or 1). The beta for a one unit difference 
represents switching from one category to the other. The beta for this “treat” effect is then the 
average difference in pain rating between the category for which treat = 0 (the reference 
group/condition) and the category for which treat = 1 (the comparison group/condition). Although 
this is more complex to conceptualise for interaction effects, the beta for the categorical interaction 
predictor “treat:phase” (for example) is also the unit change in pain ratings explained by this 
interaction (this is also within the 0-10 range of the pain scale). In this case this means that the 
interaction changes the pain rating by a value on the 0-10 scale of -0.74. Just as in multiple 
regression, to interpret the direction of the relationship between variables, the signs (plus or minus) 
of the beta coefficients are important. If the beta coefficient is negative as in this case, then the 
relationship of this variable with the dependent variable is negative (e.g., the pain rating decreases 
due to the interaction).  
With this in mind, we can interpret the the 3-way interaction of “treat:phase:arm”. In our original 
version of the analysis, “arm” was dummy coded such that the “treated arm” was the reference level 
(coded 0) and “untreated arm” had a value of 1. However, in the new Table 3 you will see that we 
have re-coded this variable so that untreated/treated have values of 0/1 respectively. This is to 
maintain consistency with the “treat” predictor variable where the reference level indicates 
“untreated”. Otherwise, as the reviewer correctly points out, interpretation of this value is 
potentially confusing. Now, the value of 0.26 has a negative sign - this indicates that adding “treated 
arm” to the model (specifically, to the “treat:phase” interaction) further decreases the pain rating by 
a value of 0.26. Please note that the new model has changed the statistics for the intercept term but 
aside from this and the change in sign for the arm terms, the statistics remain the same. 
We have updated the Results test to help readers interpret these values: “This [3-way] interaction 
indicated that pain ratings changed (with the negative sign indicating a decrease) on average by a 
further 0.26 points (t = -3.14, p = 0.002, 95% CIs: -0.10 to -0.43, Table 3) due to the additional effect 
of the treated vs. untreated arm.” 
 
Furthermore, I have a question regarding the 2-way compared to the 3-way interaction: judging 
from Figure 2, there clearly seems to be an interaction of treatment x phase, and table 3 supports 
this. Then the significant 3-way interaction is described on p. 12, and it is stated: "this indicates a 
placebo effect that is evident on both arms (treated and untreated) but is larger on the treated arm 
". This statement seems to be wrong. Judging from figure 2, adding the "arm" factor does not seem 
to explain much more of the variance than the 2-way interaction does, as the results for the treated 
and untreated arm are almost identical whether the subject was in the control or placebo group. An 
interaction involving "arm" as factor suggests that these lines are not parallel, although figure 2 
indicates the opposite. Please use follow-up tests to provide evidence that placebo effects are larger 
on the treated arm. 
Author response: As shown in Figure 2, the slope of the line for the placebo effect (right plot) on the 
treated arm (filled circles) is steeper (more negative) compared to the untreated arm; conversely, 
for the control group the slope for the treated arm is more shallow (less negative) compared to the 
untreated arm. This is what gives rise the significant interaction effect. Although the relative 
difference in slopes is subtle by view of the figure, it is nevertheless clear that there is a difference 
that corresponds to a 0.26 point change as indicated in Table 3. Linear mixed models provide larger 
statistical power than ANOVA for detecting such effects. Follow-up tests could be conducted on pairs 
of means (e.g. placebo group, post-conditioning, treated vs. untreated arm) but this would not 
provide insight into the effect of “arm” on the placebo effect, since the placebo effect is defined by 
the “treat:phase” interaction. We believe the 3-way the interaction effect is most easily interpreted 
by view of the relative relationships showed in Figure 2. 
 
Also, there is no mention of the factor "arm" in the Discussion, although much of the Results is 
dedicated to this factor. If placebo effects are similar for both the treated and untreated arm, this 
suggests that the placebo effect is non-specific. In the literature there are data to support bot this 
view, and the view that placebo effects are specific and can be limited to a single arm or finger. This 
is theoretically very important and should be included in the Discussion. 
Author response: This point has now been addressed in the Discussion: “Our results showed a 
placebo effect on both arms, which to a degree makes it a non-specific effect, although with a larger 
effect seen on the treated arm. In other words, our data suggests we have seen both arm-specific, as 
well as arm non-specific effects, which is one of the novel findings of this study.” (P20 Line8) 
 
P. 17: Expectations did not predict placebo analgesia in any group of participants. The authors 
discuss that non-conscious conditioning could be a better predictor. This may be tested by 
subtracting the pain in the conditioning phase from the pain in the pre-conditioning phase (i.e. the 
unconditioned response), and correlating this with the placebo effect (the conditioned response). 
The literature on classical conditioning shows that there is a positive correlation between UR 
amplitude and CR amplitude, and we have observed the same in some of our studies. I would 
suggest this should be included in the Results. 
Author response: We agree that this would add some insight to the results. The reviewer’s 
suggestion appears to be to conduct regression analyses of the conditioned response (conditioning 
phase mean pain ratings minus pre-conditioning phase mean pain ratings) predicting the placebo 
response (post-conditioning phase mean pain ratings minus pre-conditioning phase mean pain 
ratings). This would work if we assume no habituation effects over the 3 phases – but since we 
cannot assume this, we could expect significant regression effects as a result of greater habituation 
in some participants relative to others. Hence, the analysis would only be insightful if conducted on 
pain ratings data after subtraction of the data between the treated and untreated arms – this would 
provide a measure of the site-specific placebo effect that controls for habituation since both arms 
would be expected to habituate at the same rate.  
Another factor to consider is whether the participant was in the placebo-treated group, or 
alternatively in the control group who went through the same conditioning procedure but were 
informed that the cream was not an analgesic. An unconscious conditioning effect might be 
expected to influence both groups equally, whereas a conditioning effect that depends upon 
congruent expectations (of pain relief) would only impact the placebo treated group.  
We have conducted regression analyses (see updated Methods, Supplementary Materials, and 
Results sections) using linear mixed models to account for dependency in the data between the two 
study sessions, and including all diagnostic groups pooled together. The basic model included the 
(arm subtracted) conditioned response as a predictor of the (arm subtracted) placebo response. We 
also included the treatment group (treated vs. control) as a fixed effect to test for an interaction 
between the group and the relationship between the decrease in pain ratings during conditioning 
and the placebo response – this interaction was statistically significant (p=0.024). To explore this 
further two separate models were conducted as follow-up tests – one regression model per group 
(treated vs. control) with the conditioning pain reductions as the only predictor variable. We found 
that the conditioned pain decreases significantly predicted the placebo response only in the treated 
group (p<0.001) but not in the control group (p=0.24).  
Overall, the results show that the change in mean pain ratings from pre-to-post conditioning can be 
explained by impact of the conditioning procedure only in the treatment group, suggesting that their 
conscious expectation of pain relief (reinforced by the conditioning procedure) was an important 
factor in the resulting placebo effect. This has implications for our discussion of conscious vs. 
unconscious processes and we have updated the discussion accordingly (P19 Line 24). 
 
Reviewer #2: The authors addressed all my comments appropriately. 
Author response: Thank you 
 
(END OF REVIEWS)  
 
Abstract 
It is unclear whether a diagnosis of chronic pain is associated with an increase or 
decrease in the placebo response. The aim of this study was to use an experimental 
placebo conditioning paradigm to test if expectancy for pain relief impacts on acute 
pain perception in individuals with a chronic pain diagnosis of osteoarthritis (OA) or 
fibromyalgia (FM), compared to healthy individuals (HI). An inert cream was applied 
to the dominant forearm of participants (60 OA, 79 FM and 98 HI), randomly assigned 
to either a placebo or control group. In both groups an inactive cream was applied to 
the dominant forearm. The placebo group was told this may or may not be a local 
anaesthetic cream, while the control group was told the cream was inactive. Laser 
pain was delivered, and numerical pain intensity ratings collected before, during and 
after cream application, along with expectation of pain relief and anxiety. The 
procedure was repeated two weeks later to assess reproducibility. There was a 
significant reduction in pain in the placebo group, independent of clinical diagnosis. 
Diagnostic groups (OA,FM,HI) did not differ in their magnitude of placebo analgesia 
or expectancy of pain relief. The results were similar in the repeat session. The results 
demonstrate that individuals with chronic pain respond to experimental placebo 
analgesia in a similar and reproducible manner as healthy individuals, despite higher 
levels of psychological co-morbidity. This has implications for utilising placebo 
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Chronic pain carries a huge socioeconomic burden and substantially 2 
impacts the quality of life of affected individuals [13]. The lack of effective 3 
treatments for chronic pain, combined with our clearer understanding of 4 
underlying neurophysiological processes, has led to current research switching 5 
its attention from peripheral to central pain processing [41]. There is evidence 6 
of dysfunction within the endogenous pain inhibition system in most chronic 7 
pain syndromes [22,43]. This has resulted in the investigation of alternative 8 
techniques to utilise endogenous pain control mechanisms, for example 9 
placebo analgesia, which has been shown to have a significant impact on the 10 
subjective perception of pain [30].  11 
The placebo effect, previously considered to be a nuisance variable, has 12 
since been shown to have substantial potential to improve patient outcomes 13 
[10]. Several commonly investigated techniques are used to induce placebo 14 
analgesia, with classical conditioning and manipulation of expectation being the 15 
most prominent [29].  16 
In healthy individuals, placebo analgesia can be induced using a 17 
conditioning technique whereby the application of a sham anaesthetic cream is 18 
paired with the surreptitious lowering of an experimental pain stimulus. We and 19 
others have shown measurable and stable physiological and behavioural 20 
changes following such placebo (sham) treatments [14,31,46,47,53,54]. 21 
Placebo analgesia is reproducible in healthy individuals, and placebo 22 
responders tend to display particular cognitive traits, such as higher levels of 23 



































































It has been suggested that placebo analgesia may be mediated by 1 
reduced negative emotional processing [3,4,35]. Pain normally increases 2 
negative emotions, which in turn increases the subjective experience of pain 3 
[37]. Conversely, analgesic administration induces the expectation of reduced 4 
unpleasant symptoms, which reduces anxiety and, consequently, actual 5 
symptoms of unpleasantness [3,4,15,38]. Chronic pain patients have 6 
psychological co-morbidities such as anxiety, depression, pain catastrophizing 7 
[32,48] and cognitive impairments [8]. For this reason, several models 8 
examining the role of expectancy and anxiety in modulation of pain by placebo 9 
have predicted reduced placebo analgesia in patients with chronic pain when 10 
compared to healthy individuals [33,35,32,48].  11 
Existing data, however, shows that high levels of psychological co-12 
morbidity do not affect the response to placebo in patients with chronic low back 13 
pain [5], and one study showed enhancing expectation improved the analgesic 14 
effects of acupuncture treatment in individuals with osteoarthritis [24]. In fact, a 15 
recent meta-analysis suggests individuals with chronic pain respond better to 16 
placebo analgesia than healthy individuals [16]. However, it should be noted 17 
that this conclusion was based on comparing average effect sizes from studies 18 
containing either pain patients or heathy individuals, but not having both groups 19 
within the same study. 20 
In this study we aimed to examine the behavioural response to placebo 21 
analgesia in individuals with Osteoarthritis and Fibromyalgia when compared 22 
to pain-free healthy individuals, using a standardised, 2-stage conditioning 23 
technique (verbal suggestion and the adjunctive procedure of sham analgesic 24 



































































the reproducibly of a placebo effect in individuals with chronic pain over two 1 
sessions and explored the dependency of the placebo effect on the conditioning 2 





The study was approved by the Greater Manchester West NRES 8 
Committee and the University of Manchester Ethics Committee. 60 patients 9 
with osteoarthritis (OA) and 79 patients with fibromyalgia (FM) were recruited 10 
from the Musculoskeletal Pain Clinics throughout the North West of England 11 
and from primary care practices that are part of the North West Primary Health 12 
Care Research Network. 98 pain-free healthy individuals (HI) with no history of 13 
ongoing pain symptoms were also recruited. Fibromyalgia patients fulfilled the 14 
2010 American College of Rheumatology (ACR) criteria for the diagnosis of FM 15 
[53]. OA patients were diagnosed according to the standard ACR criteria [1]. 16 
All participants were over the age of 18, with no diagnosed neurological or 17 
morbid psychiatric illness, no peripheral vascular disease and no allergies to 18 
local anaesthetic creams (such as EMLA). Written informed consent was 19 
obtained prior to participation in the study. Handedness was not part of the 20 






































































The experimental design included both between-subject factors and 1 
within-subject factors. Between-subject factors were the diagnostic categories 2 
(OA, FM, and HI) and whether the participant underwent the placebo (sham) 3 
treatment or a control experiment with no treatment. Regarding the treatment 4 
factor, participants within each of the three diagnostic categories (OA, FM, and 5 
HI) were randomized into one of two experimental groups: a Placebo (P) group 6 
or a control (C) group, undergoing either an experimental placebo procedure or 7 
a control procedure respectively on the right arm (see Figure 1 for details). 8 
Within-subject factors included the treatment session (1 and 2, on separate 9 
days) and the phase of the experiment (pre-conditioning, conditioning and post-10 
conditioning). 11 
Randomisation: Participants were randomised into treatment and control 12 
groups with a 2:1 ratio respectively. This imbalanced design sought to ensure  13 
that there were a sufficient number of participants in each of the sham-treated 14 
diagnostic sub-groups (minimum 35 per sub-group based on a power 15 
calculation) to obtain robust estimates of the intra-cluster correlation coefficient 16 
for each, while also allowing for attrition or other causes of data loss. 17 
 18 
Laser stimuli 19 
Laser heat stimuli (with a duration of 150 ms and a beam diameter of 20 
15 mm) were applied to the dorsal surface of the both right and left forearms 21 
using a CO2 laser stimulator. Between each pulse there was an inter-stimulus-22 
interval of 10s. After each stimulus the laser was randomly moved over an area 23 
of 3 × 5 cm to avoid skin damage, habituation or sensitisation. The participants 24 



































































(NRS) with 0 corresponding to no sensation, 4 corresponding to pain threshold, 1 
7 moderate pain and 10 worst pain imaginable. Participants were trained to rate 2 
each stimulus prior to starting the experiment. Once the participants reached a 3 
moderately painful level (7 on the pain scale) the laser was stopped, and the 4 
energy required to elicit a rating of 7 was recorded. This procedure was 5 
repeated a minimum of three times for each arm to ensure that ratings remained 6 
reasonably consistent. The level 7 was set independently for each arm. 7 
Participants were then asked to rate their level of state anxiety using a 0 to 100 8 
visual analogue scale (VAS) (0 no anxiety - 100 extreme anxiety), this was 9 
repeated at each treatment phase and at the end of the experiment.  10 
 11 
Pre-experiment questionnaires 12 
Prior to starting the experiment, participants were asked to complete the 13 
following questionnaires which were used to assess levels of psychological 14 
distress and other psychological variables that predict pain experience: the 15 
State-Trait Anxiety Inventory (STAI) [42], the Pain Anxiety Symptoms Scale 16 
(PASS) [28], the Hospital Anxiety and Depression Scale (HADS) [57], the Pain 17 
Catastrophizing Scale (PCS) [45], the Life Orientation Test (LOT-R) [40] and 18 
the Healthy Anxiety Inventory (HAI) [39]. 19 
 20 
Procedure 21 
The procedure followed a strict script, followed verbatim for both the 22 
placebo and control groups: Participants were informed which group they will 23 
be in after signing the consent form. Participants in the placebo treatment group 24 
were told ‘you may or may not receive a local anaesthetic cream to your right 25 



































































an inactive cream on both arms. Whereas participants in the control group were 1 
told explicitly that they would receive an inactive cream on both arms.  2 
Therefore, the right arm was conditioned within the placebo group and not in 3 
the control group. We have previously shown this to be a successful method of 4 
inducing placebo conditioning [52,53]. The procedure schematic is represented 5 
in Figure 1. In the following, the three experimental phases of the experiment 6 
are described as per the placebo (sham-treated) group. 7 
 8 
Insert Fig 1 about here 9 
 10 
Pre-conditioning phase (Phase 1) 11 
Before application of the cream participants were asked to rate 20 laser 12 
stimuli using the NRS 0–10 pain scale - 10 stimuli to the dorsum of the left 13 
forearm and 10 stimuli to the dorsum of the right forearm. All pulses were 14 
delivered at the individually identified laser energy corresponding to the 15 
moderately painful level 7.  16 
 17 
Conditioning phase (Phase 2) 18 
Application of sham local anaesthetic (placebo) cream: Aqueous cream, 19 
containing paraffin oils was placed on a strip of occlusive, transparent, film 20 
dressing (Tegaderm, 3M Healthcare, St Paul, MN, USA). The cream, covered 21 
by the dressing, was then placed upon the entire laser stimulation area of both 22 
right and left forearms. The occlusive dressing held the cream in position, and 23 
this was left in place for 30 min during which time participants were told that the 24 



































































(using the occlusive dressing), was similar to those commonly used for the local 1 
anaesthetic cream EMLA. This was important to reinforce conditioning. Each 2 
participant was then asked to rate their expectations regarding pain reduction 3 
by indicating on a “Expectation for Pain Relief Scale” using a 0 to 100 VAS (0 4 
= no expectation of pain relief - 100 = high expectation of pain relief) [49]. After 5 
30 min the dressing was removed, and the cream was wiped off. 6 
Following removal of the cream, participants again received 10 laser 7 
stimuli to each forearm, but at a surreptitiously reduced energy level just on 8 
their right forearm. The reduced energy level corresponded to their individually 9 
identified non-painful level 3, while all pulses delivered to the left forearm were 10 
still maintained at a laser energy corresponding to the moderately painful level 11 
7. The surreptitious lowering of the laser energy delivered to the right forearm 12 
(and not the left forearm) made it easier for participants to compare the 13 
sensation directly to their experience of the laser on the other arm. This was a 14 
method we had previously used and allowed us to identify site-specific effects 15 
vs. non-specific effects that generalise to other regions of the body [52]. This 16 
was intended to reinforce the perception that participants had received an 17 
active local anaesthetic cream to the right forearm only and that it was having 18 
an effect. Participants rated the laser pulses using the 0–10 NRS pain scale. 19 
Participants were then asked again to rate their level of anxiety and expectation 20 
of pain relief, before entering, almost immediately, into the post-conditioning 21 
phase of the experiment. 22 
 23 



































































In this post-phase, laser energy applied to the right forearm was 1 
surreptitiously raised to the pre-conditioning level, so both arms received laser 2 
energy at the participant’s original level 7 (perceived to be moderately painful). 3 
Participants were asked to rate another 10 pulses on each forearm at this level. 4 
 5 
Control group 6 
The intention of the control group was to control for the effects of verbal 7 
suggestion on placebo conditioning. Participants in the control group 8 
experienced exactly the same procedure in pre-phase, conditioning phase and 9 
post-phase as the placebo group, the only difference being was that they were 10 
informed throughout the experiment that, i) the cream was inactive and ii) that 11 
the laser stimulus would be turned down to a non-painful level just on the right 12 
forearm, during the conditioning phase. By informing control participants that 13 
they were receiving an inactive cream, and that laser energy would be reduced, 14 
this controlled for the effects of verbal suggestion, but potentially allowed for 15 
unconscious conditioning effects (occurring due to the participants’ experience 16 
of experimental pain reduction) that matched those of the placebo group. 17 
 18 
Reproducibility  19 
A least two weeks after the first session, participants returned for a 20 
repeat session. The two sessions are henceforth referred to as Session 1 and 21 
Session 2. In Session 2, participants were assigned to the same group and 22 
given exactly the same treatment and instructions as in Session 1. To minimise 23 



































































treatment they received in the first session would not impact upon the effects 1 
of the treatment they received in the second session. 2 
 3 
Data analysis  4 
We used linear mixed effects models (LMMs) to test for the presence of 5 
placebo effects and to test the hypothesis of group differences in placebo 6 
effects. Details of the models used are in Supplementary Materials. The 7 
“phase” effect (change in pain ratings from phase 1 to phase 3) was included 8 
to test for placebo effects, with “arm” (treated and non-treated) as a separate 9 
fixed effect that was expected to interact with phase. We also examined 10 
whether there was an effect of session. Analyses adjusted for the potential 11 
confounding effect of the pain rating reported during conditioning (phase 2) of 12 
the experiment by using the mean pain rating from phase 2 as a participant-13 
level fixed-effect covariate. We also controlled for the laser energy used to elicit 14 
pain during the experiment, and participants’ age and gender, as fixed effects. 15 
Participants were treated as random effects to allow overall pain ratings and 16 
placebo effects to vary across participants (see Supplementary Materials for 17 
details). Because we used LMMs, we examined the distribution of the residuals 18 
of the pain ratings were fitting to the model. Normal probability plots showed 19 
that the distribution of the residuals was normal with approximately equal 20 
variance over conditions and groups. All statistical tests were 2-sided, with α = 21 
0.05. Analyses were performed using both R and Matlab 2019a (MathWorks 22 
Inc.) softwares. 23 
Intraclass correlation coefficients (ICCs) were calculated to examine the 24 



































































data from the treated arm only. For this calculation we used LMMs to identify 1 
variance components for the random effects (participants) and model error term. 2 
Further details are in Supplementary Materials.  3 
In addition to investigating placebo effects on pain ratings, we also 4 
tested for conditioning-induced changes in anxiety and expectation, primarily 5 
focussing on ratings collected both immediately prior and subsequent to 6 
conditioning (Anx3 to Anx4, and Exp1 to Exp2 – see Figure 1). Similar LMMs 7 
were fitted to this data as per the placebo pain ratings models (model details in 8 
Supplementary Materials). We also tested for group differences and trends over 9 
time in anxiety ratings over the whole experiment (Anx1 to Anx5). Finally, we 10 
tested whether these state variables influenced the response to sham treatment 11 
by fitting additional pain rating models that included these state variables 12 
(expectation and anxiety) as either main effects or interactions with experiment 13 
phase (pre to post-conditioning).  14 
Finally, we investigated whether the conditioning procedure was 15 
effective at inducing placebo responses by using LMMs to compare the groups 16 
(placebo vs. control) in the extent to which decreases in pain ratings measured 17 
during the conditioning procedure predicted decreases in pain ratings in the 18 
post-conditioning phase. Importantly, the analysis focussed on site-specific 19 
placebo responses by first subtracting mean pain ratings on the untreated arm 20 
from those on the treated arm; this also provided control over the confound of 21 
habituation effects that might otherwise cause a spurious correlation between 22 
conditioning phase and post-conditioning phase pain ratings (caused by 23 



































































expected to habituate at the same rate. Further details of the models are in 1 
Supplementary Materials. 2 
 3 
Results 4 
Characteristics of the diagnostic groups 5 
237 participants completed the study (60 OA, 79 FM and 98 HI). A 6 
summary of characteristics is shown in Table 1. 7 
 8 
Insert Table 1 about here 9 
 10 
Laser energy 11 
The energy levels required to elicit a moderately painful subjective level 12 
7 rating were similar between OA and HI groups (HI=17.85±3.1 mj/mm2, 13 
OA=18.8±3.36 mj/mm2, p=0.06), but significantly lower in FM participants 14 
(FM=16.2±4 mj/mm2, HI vs FM p<0.001, OA vs FM p<0.001). Hence, these 15 
values were included as a nuisance covariate in statistical analyses of placebo 16 
effects. 17 
 18 
Psychometric tests 19 
One-way ANOVA on the diagnostic groups showed a highly significant 20 
effect of diagnosis on certain psychological variables that had previously been 21 
shown to predict pain experience (p<0.001; Table 2), with OA, FM and HI 22 
groups all showing significantly different outcomes. Post-hoc data indicated that 23 
FM patients reported significantly increased levels of psychological distress 24 



































































pain anxiety symptoms where FM and OA displayed similar outcomes (PASS 1 
avoidance, p=1; PASS fearful thinking p=0.074).  2 
 3 
Insert Table 2 about here 4 
 5 
The placebo effect 6 
There was a placebo effect evident from a significant 2-way interaction 7 
between treatment group and phase of the experiment, indicating that pain 8 
ratings were more decreased, on average, by 0.74 (out of 10 on the numerical 9 
rating scale) from pre to post-conditioning in the placebo treatment group 10 
compared to the control group (t = -5.14, p < 0.001, 95% CIs: -0.99 to -0.50, 11 
Table 3). Additional but weaker variance in pain ratings was accounted for by 12 
a 3-way interaction between treatment group (placebo treatment vs. control), 13 
phase of the experiment (pre vs. post conditioning) and arm (treated vs. 14 
untreated). This interaction indicated that pain ratings changed (with the 15 
negative sign indicating a decrease) on average by a further -0.26 points (t = -16 
3.14, p = 0.002, 95% CIs: -0.10 to -0.43, Table 3) due to the additional effect of 17 
the treated vs. untreated arm. Overall, this indicates a placebo effect that is 18 
evident on both arms (treated and untreated) but is larger on the treated arm. 19 
These effects are plotted as fitted group means and CIs of the mean in Figure 20 
2. A Likelihood Ratio Test provides strong support for a model of the pain 21 
ratings that includes these interactions compared to a control model without 22 
these interactions (LR = 152.6, p<0.001; comparison of model 2 vs. model 1 in 23 




































































Insert Table 3 and Figure 2 about here 1 
 2 
Although, on average, there was a significant placebo effect, there was 3 
considerable variation between participants, evident from the random effect 4 
coefficients. The random effect (i.e. participants) for the phase slope (change 5 
from pre to post-conditioning) in the model, indicating individual variability in the 6 
magnitude of the placebo response, had a standard deviation of 0.89 (95% CIs: 7 
0.80 to 0.98) points on the 0-10 rating scale, even after accounting for the fixed 8 
effect of treatment group in the model. This indicates a considerable variability 9 
between participants in the placebo response within the treatment and control 10 
groups. 11 
However, we did not find evidence that the placebo effect varies 12 
significantly across diagnostic groups (OA, FM, HI). Firstly, a Likelihood Ratio 13 
Test did not favour strongly enough a model in which diagnostic group 14 
interacted with the factors of treatment group, experiment phase, and arm 15 
treated (LR = 23.2, p = 0.06). Secondly, results from the model including these 16 
interaction terms involving diagnostic group did not reveal any significant 17 
interactions. Violin plots (Figure 3) show that all three diagnostic groups who 18 
were treated with placebo (i.e. sham treatment groups) showed lower levels of 19 
reported pain following application of the placebo cream compared to their 20 
control group counterparts, and this was the case in both sessions. 21 
 22 
Insert figure 3 about here 23 
 24 



































































We tested a further mixed model (model 4 – see Supplementary 1 
Materials) in which interaction terms were added involving the factor Session. 2 
A Likelihood Ratio Test found that this did not improve model fit, suggesting 3 
that placebo effects were not depending on the experimental session. To 4 
formally investigate test-retest reliability of the placebo effect over sessions, 5 
intra-cluster correlation coefficients (ICCs) were calculated on mean pain 6 
ratings post-conditioning, after adjusting for pre-conditioning mean pain ratings. 7 
The ICC for the sham treatment groups was 0.77, indicating moderately good 8 
test-retest reliability, while for the control groups the ICC was weak at 0.21. 9 
Breaking down the ICC for the treatment groups into diagnostic sub-groups, the 10 
ICCs for the OA, FM and HC groups were 0.78, 0.80 and 0.72 respectively. To 11 
visualise the relative difference in placebo effects from session 1 to session 2, 12 
Figure 3 plots lines indicating the placebo effect across sessions, for each 13 
participant. 14 
 15 
Expectation of pain relief 16 
Expectation of pain relief was reported by participants twice during the 17 
experiment (pre and post cream application), and the change in expectation 18 
ratings was analysed (Exp1-Exp2). There was a clear effect of placebo 19 
treatment (p<0.001, Figure 4, Table 4), however no effect of session or 20 
diagnosis. 21 
 22 





































































Anxiety levels were measured at 5 time-points (Anx1 to Anx5, Table 5) 1 
throughout the experiment. There was a clear effect of diagnosis on anxiety 2 
(F=27.47, p<0.001, Figure 4), with FM patients rating higher anxiety levels than 3 
both OA and HC participants throughout the experiment (Figure 5).  There was 4 
also a significant linear trend over time in anxiety ratings from Anx1 to Anx5 5 
(F=16.98, p<0.001) and anxiety ratings were overall lower in session 2 6 
compared to session 1 (F=10.55, p=0.001). However, after adjusting for pre-7 
treatment anxiety levels, there was no indication that changes in anxiety during 8 
the conditioning phase (i.e. change in anxiety levels between time-points Anx3 9 
and Anx4) were specifically influenced by diagnosis, treatment or session 10 
(Figure 4, Table 4).  11 
 12 
Placebo effect – Independent of expectation and anxiety 13 
The placebo effect did not appear to be predicted by, or mediated by, 14 
expectation or anxiety. Specifically, we found that adjusting for either the 15 
baseline levels, or for the pre-post conditioning changes, in expectation or 16 
anxiety within the model of placebo effects did not remove the placebo effect. 17 
Likelihood Ratio Tests did not favour models that included these variables as 18 
either main effects or interacting with terms in the model that included phase 19 
(pre vs. post treatment). 20 
 21 
Insert Table 5 and Figure 5 about here 22 
 23 
Differential prediction of the placebo response by conditioning responses 24 



































































Additional linear mixed models tested for the prediction of site-specific 1 
placebo responses (defined by relatively greater decreases in mean pain 2 
ratings on the treated vs. untreated arm) from the reductions in pain experience 3 
during conditioning (see models 9 to 11 in Supplementary Materials). We 4 
initially tested (model 9) whether the linear relationship between conditioning 5 
decreases in pain and placebo responses differed between the placebo and 6 
control groups. The rationale is that since the control group went through the 7 
same conditioning procedure as the placebo group, but were informed that the 8 
cream was not an analgesic, this analysis provides further insight into the role 9 
of conscious expectation in the efficacy of the conditioning procedure. 10 
Specifically, if conditioning required only unconscious processes, the 11 
relationship between conditioned and placebo responses would be expected 12 
not to differ between groups. However, we found that there was a statistically 13 
significant interaction between the fixed effect of group and the conditioning 14 
phase decrease in pain in the model (beta = 0.12, 95% CIs: 0.02 to 0.22, t = 15 
2.27, p = 0.024, Table 6). To explore this further, two separate models (models 16 
10 and 11) were conducted as follow-up tests, showing that the conditioning-17 
related decreases in pain significantly predicted the placebo response only in 18 
the treated group (beta = 0.20, 95% CIs: 0.13 to 0.27, t = 5.93, p < 0.001, Table 19 
6) but not in the control group (beta = 0.05, 95% CIs: -0.03 to 0.12, t = 1.18, p 20 
= 0.241, Table 6). For illustration purposes, the relationships are plotted in 21 
Figure 6 using only the data from session 1 (for which there is the largest 22 
sample of data). Overall, the results show that the placebo response can be 23 



































































suggesting that the effect of conditioning on the placebo effect depends upon 1 
congruent expectations (of pain relief) that were only present in that group.  2 
 3 
Insert Table 6 and Figure 6 about here 4 
 5 
Discussion 6 
We investigated the reproducibility of placebo analgesia across patients 7 
with OA and FM, as well as pain-free HI. We also studied whether expectation 8 
of pain relief, psychological distress and changes in anxiety during the 9 
procedure were predictors of placebo responses. Lastly, we tested whether 10 
placebo responses could be predicted from decreases in pain during 11 
conditioning. We found that despite psychological co-morbidities, patients with 12 
OA and FM displayed similar experimental placebo analgesic responses to 13 
their HI counterparts. This included similar levels of reproducibility and 14 
expectations of pain relief. While findings suggested that the placebo response 15 
is not predicted or mediated by participants’ judgements of their changes in 16 
expectation or anxiety, we did find that it was only in the placebo group (who 17 
had a conscious expectation of pain relief) that there was a relationship 18 
between conditioning and post-conditioning reductions in pain, suggesting that 19 
the placebo effect depends upon congruent expectations of pain relief. 20 
Previous evidence for the efficacy and reproducibility of placebo 21 
analgesia mainly exists from experimentally evoked pain studies in healthy 22 
individuals [2,9,14,51,52,54]. Whereas, evidence for positive placebo analgesic 23 
responses and reproducibility in individuals with chronic pain primarily comes 24 



































































[8,20,21,56]. Here we have shown that placebo responses to experimentally 1 
induced pain are as equally reproducible in individuals with chronic pain, as in 2 
healthy individuals. As far as we are aware, this is the first study to compare 3 
responses between these groups within the same study. 4 
Placebo responders and the placebo response have been previously 5 
linked to cognitive traits, such as lower levels of state anxiety [31] and reduced 6 
negative emotional processing [3,35]. In contrast, the psychological co-7 
morbidities associated with chronic pain conditions, such as depression and 8 
anxiety, have been implicated in reducing the effectiveness of placebo 9 
analgesia in chronic pain patients [33,30,46]. Based on this, we anticipated that 10 
OA and FM patients would exhibit a reduced placebo response compared to 11 
their HI counterparts, but in our study this was not the case. 12 
Correlations between changes in expectation with the magnitude of 13 
placebo analgesia have previously been observed [34,36]. This is thought to 14 
occur because sensory experiences such as pain are influenced by the 15 
interaction between expectations (e.g. of pain relief) and sensory information, 16 
such as nociception. Because expectancy is believed to play a significant role 17 
in initiating placebo effects, individual differences in placebo analgesia may 18 
also be driven by differences in expectancy. Where placebo responses are 19 
large for a particular individual or situation, this can be seen as a triumph of 20 
expectation over current sensory information [32]. Interestingly, while 21 
participant ratings of expectation or anxiety did not predict placebo responses, 22 
there was only a relationship between conditioning phase and post-conditioned 23 
reductions in pain ratings in the placebo group. This is consistent with the view 24 



































































unconscious conditioning processes for placebo effects to be realised [44]. 1 
Insight on the discrepancy between these two analyses comes from recent 2 
debate about the role of predictive coding schemes in the brain [7] in which 3 
prior experiences (e.g. conditioning) may generate ‘unconscious predictions’. If 4 
partially unconscious, participants may not accurately report on their 5 
expectations but may nevertheless by influenced in their perception and 6 
reporting of pain. This may also account for the placebo response observed on 7 
the untreated arm in our study: our results showed a placebo effect on both 8 
arms, which to a degree makes it a non-specific effect, although with a larger 9 
effect seen on the treated arm. In other words, our data suggests we have seen 10 
both arm-specific, as well as arm non-specific effects, which is one of the novel 11 
findings of this study. 12 
Consistent with our observation of equivalent placebo responses 13 
between diagnostic groups, expectation of pain relief, and relative increases in 14 
expectation through conditioning, were also similar across diagnostic groups 15 
and healthy controls. This suggests that, despite living with chronic pain, 16 
individuals with OA and FM still have normal expectancy of pain relief, as well 17 
as normal updating of expectancy by conditioning. This is of interest because, 18 
although it was not assessed in our study, individuals with chronic pain are 19 
more likely to have numerous (positive or negative) healthcare experiences 20 
compared to healthy individuals [13], which could affect the expectation of pain 21 
relief in future treatments [17]. With our chronic pain cohort, their history of pain, 22 
previous treatment experiences, and the refinement of their expectations and 23 
beliefs that may result from those experiences, did not appear to interfere with 24 



































































We also examined anxiety levels during the placebo/sham and control 1 
procedures. Unlike expectations of pain relief, we saw a significant difference 2 
in baseline levels of anxiety between diagnostic groups. This is consistent with 3 
the known psychological comorbidities often experienced by patients with 4 
chronic pain, including anxiety and depression [11], pain catastrophizing [19] 5 
and cognitive impairments [7,18]. While previous studies suggest that 6 
psychological symptomatology can predict the magnitude of the placebo 7 
response, but our findings have been contradictory. Wasan et al. found that 8 
high levels of psychopathology, including pain-related anxiety, are associated 9 
with heightened placebo analgesia in chronic lower back pain patients [49], 10 
while Lyby showed that increased levels of stress and fear of pain reduces the 11 
placebo analgesic response in healthy participants [27]. We have previously 12 
reported that low state anxiety is a significant predictor of placebo response in 13 
healthy individuals [33]. Contrary to these findings, our current data shows that 14 
although anxiety levels between diagnostic groups varied significantly, the 15 
placebo response did not. Although FM patients showed higher levels of 16 
anxiety than both OA and HI participants throughout the experiment, the FM 17 
placebo response was no different. The disparity to previous literature could be 18 
due to differences in the way participants were selected, differences in the 19 
methods used to assess psychological variables (we assessed anxiety 20 
whereas Lyby assessed fear of pain and stress), or differences in the placebo 21 
paradigm (e.g. our study used conditioning and Wasan’s study did not) [49,27].  22 
Throughout our experiment we observed a significant linear trend in the 23 
reduction of anxiety in all diagnostic groups over time (highlighted in Figure 5). 24 



































































reductions in anxiety levels in IBS patients [26], but our study is the first, of 1 
which we are aware, that observes equivalent changes in anxiety in OA and 2 
FM patients. It is also of interest to note that any decrease in anxiety was not 3 
specific to the placebo treatment, as it was also evident in the untreated control 4 
groups. Previous research has also failed to elucidate a clear and consistent 5 
relationship between changes in anxiety and placebo analgesia. Some 6 
evidence suggests changes in anxiety might contribute to the placebo 7 
analgesic response [12], while other evidence suggests placebo analgesia is 8 
the causal factor in a reduction in state anxiety [25]. While the mechanistic 9 
contribution of changes in anxiety are unclear, our results do indicate that 10 
changes in anxiety are not dependent on initial levels of anxiety, a finding that 11 
has not been previously reported. 12 
A limitation of our study is the possibility of selection bias that might limit 13 
generalisation of the findings. Specifically, a meaningful proportion of patients 14 
in our study were recruited from the same rheumatology clinic, which means 15 
our results apply to a specific demographic. For instance, patients from the 16 
same area may have had similar healthcare experiences, which has been 17 
shown to alter expectations [17].  18 
Regarding clinical implications, our results suggest that individuals with 19 
FM and OA can modulate their responses to experimental pain as efficiently as 20 
healthy individuals. In this context, given equally efficient endogenous 21 
analgesia across diagnostic groups, our findings suggest potential for the 22 
exploration of new treatment strategies that enhance the placebo response, or 23 
otherwise utilise endogenous analgesia in these patients, in order to improve 24 



































































The finding that experimental placebo responses in both OA and FM 1 
groups were reproducible has some potentially important implications for 2 
clinical trial design. The variability of placebo response between individuals is 3 
a major problem, particularly for early or small clinical trials of analgesics [12]. 4 
One approach to this has been to exclude placebo responders during a pre-5 
screening process (run-in trials) [25]. However, this results in conducting trials 6 
on non-representative populations of patients. An alternative strategy is to 7 
balance the number of placebo responders in each arm using an experimental 8 
placebo procedure to screen for responders/non-responders. However, the 9 
validity of the screening procedure depends on how reproducible the placebo 10 
response is. Our results show that experimental placebo analgesia is 11 
sufficiently reproducible to justify exploring these approaches for balancing 12 
placebo responders across arms of a clinical trial. 13 
In summary, by using standardised method for inducing placebo 14 
analgesia, we found similarly reproducible changes in expectancy, anxiety and 15 
pain experience, as a result of experimental placebo, in individuals with OA and 16 
FM compared to pain-free healthy volunteers. Treatment approaches seeking 17 
to maximise placebo analgesia may therefore have equal chance of success in 18 
both OA and FM populations. 19 
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Figure legends 1 
Figure 1:  2 
Study design over time showing the various points at which participants rated 3 
laser intensity (Laser Phase 1-3), anxiety levels (ANX1-5) and expectation of 4 
pain relief (EXP1-2). The difference between the experimental groups 5 
[placebo treated arm (A), placebo untreated arm (B), control treated arm (C), 6 
control untreated arm (D)], depended on how the laser energy in phase 2 was 7 
manipulated. In all cases inert aqueous cream was applied to both forearms. 8 
In the placebo group the right forearm was conditioned to associate the cream 9 
with pain reduction by surreptitiously reducing the laser energy level (A), while 10 
the left forearm received the painful laser energy (B). The control group were 11 
told explicitly that the cream was inert and that the laser energy would be 12 
reduced on their right forearm (C), thereby eliminating the effects of 13 
conditioning, while their left forearm received the painful laser energy (D). 14 
Laser pulses lasted 150 ms, with a beam diameter of 15 mm. Energy levels 15 
required to elicit a level 7 response on the pain rating scale ranged between 16 
6.1 and 27.6 mj/mm2. 17 
Figure 2. Plot showing a change in pain rating due to the interaction between 18 
treatment (placebo vs control), phase (pre vs post conditioning phase) and 19 
arm (treated vs. untreated). Here we see a clear placebo effect on both arms 20 
(treated and untreated) which is greater on the treated arm which received 21 
conditioning. Circles are fitted values and error bars are 95% confidence 22 
intervals 23 
Figure 3. Violin plots of subject means change in pain rating (phase subtracted 24 



































































following cream application than in the control group. This effect was 1 
reproducible in both sessions. Group, treatment and session effects are 2 
displayed as violins, with session 1 & 2 paired with lines. A perfectly horizontal 3 
line for a participant would indicate the same magnitude of placebo response; 4 
a slope to the line indicates a change in magnitude. OA = osteoarthrosis, FM = 5 
fibromyalgia and HI = healthy individual groups. 6 
Figure 4. Descriptive plots showing change in pain (A), expectation (B) and 7 
anxiety (C) following the placebo and control cream in osteoarthrosis (OA), 8 
fibromyalgia (FM) and healthy (HI) groups. A. Change in Pain Rating between 9 
Phases P1 and P3 shows greater changes in pain across all diagnostic groups 10 
following the placebo opposed to the control treatment. (B) Change in 11 
Expectation of Pain Relief between EXP1 and EXP2 shows an increased 12 
change in expectation following placebo treatment. Here lower values indicate 13 
a greater increase in change and (C) the Change in Anxiety Rating between 14 
ANX3 and ANX4 time-points shows no difference between Placebo and Control 15 
treatment groups. Error bars indicate SEM. 16 
Figure 5. A descriptive plot showing reported VAS anxiety levels at 5 time-17 
points, ANX1-5, during the experiment. Osteoarthrosis patients (OA) and 18 
healthy individuals (HI) reported similar levels of anxiety at all 5 time-points 19 
during the experiment, while fibromyalgia (FM) patients rated significantly 20 
higher anxiety levels throughout. Error bars indicate SEM. 21 
Figure 6. Scatter plots (with least-squares lines) showing site-specific 22 
decreases in pain from the conditioning phase as a predictor of the site-specific 23 
placebo response in each group (placebo and control). The site-specific 24 



































































arm minus the untreated arm) in the post-conditioning phase minus the pre-1 
conditioning phase (P3-P1). Similarly, the site-specific decrease in pain during 2 
conditioning is calculated as the mean pain ratings (for the treated arm minus 3 
the untreated arm) in the conditioning phase minus the pre-conditioning phase 4 
(P2-P1). A significant prediction is only observed in the placebo group (for 5 



































































 We found equivalent and reproducible changes in expectancy, anxiety and pain 
experience as a result of an experimental placebo procedure in individuals with 
OA and FM compared to pain-free healthy volunteers.  
 The placebo effect did not appear to be predicted by or mediated by expectation 
or anxiety. 
 Treatment approaches seeking to maximise placebo analgesia may have equal 
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Table 1: Characteristics of the osteoarthritis (OA), fibromyalgia (FM) and pain-free healthy (HI) 
participants. Participants were assigned into Placebo and Control groups. N: numbers of 
participants in each group. SEM: Standard Error of the Mean.  
 
Characteristic Control Group (n = 87) Placebo/Sham Treatment Group (n = 150) 
 N (%) of 
control 
group) 




N (%) of placebo 
group) 




OA 22 (25%) 58.8±1.47 9 (39%) 38 (25%) 60.9±1.8 18 (47%) 
FM 24 (28%) 50.9±1.9 20 (83%) 55 (37%) 51.3±1.37 48 (87%) 
HI 41 (47%) 34.8±1.76 27 (66%) 57 (38%) 38.3±1.59 32 (56%) 
Age (yrs ± SEM) 46±1.6 49±1.2 
 

















Table 2: One-way ANOVAs on the diagnostic groups for psychometric measures. 
Questionnaire OA FM HI 
ANOVA 
(p-value) 
Post hoc (p-value) 










































































































































































































Mean ± SEM. Bonferroni post hoc tests highlight differences and similarities between the diagnostic 
groups.  
STAI, State-Trait Anxiety Inventory; HADS, Hospital Anxiety and Depression Scale; HAI, Healthy 
Anxiety Inventory; LOT-R, Life Orientation Test; PCS, Pain Catastrophizing Scale; PASS, Pain 
Anxiety Symptoms Scale. 









Table 3: Fixed effects from Model 2 (for models, see Supplementary Materials), including interactions 
between treatment (placebo vs control), phase (pre vs post conditioning phase) and arm (treated vs. 
untreated) to test for the presence of a placebo effect. Beta coefficients are unstandardized and 
categorical predictor variables are dummy coded, such that beta coefficients are interpretable in terms 
of the original 0-10 pain scale (e.g. a beta value of 1 indicates a change of 1 on the pain scale). 




 Coefficients ANOVA contrasts 
Parameter beta SE t p value CI-95%, lower CI-95%, upper F DF1 DF2 p value 
(Intercept) 5.60 0.46 12.25 p<0.0001*** 4.70 6.49 150.17 1 23882 p<0.0001*** 
group -0.10 0.16 -0.61 p=0.544 -0.41 0.22 0.96 2 23882 p=0.358 
 -0.25 0.18 -1.37 p=0.171 -0.61 0.11     
treat 0.25 0.13 1.89 p=0.059 -0.01 0.51 3.56 1 23882 p=0.059 
session 0.02 0.11 0.17 p=0.866 -0.19 0.23 0.03 1 23882 p=0.084 
phase -0.49 0.10 -4.83 p<0.0001*** -0.69 -0.29 23.37 1 23882 p<0.0001*** 
arm 0.48 0.06 7.39 p<0.0001*** 0.61 0.35 54.67 1 23882 p<0.0001*** 
age -0.02 0.01 -2.90 p=0.004* -0.03 0.00 8.39 1 23882 p=0.0038* 
gender -0.13 0.13 -1.03 p=0.304 -0.37 0.12 1.06 1 23882 p=0.304 
laser energy -0.18 0.17 -1.08 p=0.278 -0.50 0.14 1.18 1 23882 p=0.278 
phase2_mean 0.25 0.01 18.15 p<0.0001*** 0.22 0.28 329.33 1 23882 p<0.0001** 
treat:phase -0.74 0.13 -5.86 p=0.0002** -0.99 -0.49 34.36 1 23882 p=0.0001*** 
treat:arm 0.09 0.07 1.24 p=0.217 0.24 -0.05 1.53 1 23882 p=0.207 
phase:arm 0.14 0.07 -2.14 p=0.032* 0.27 0.01 4.58 1 23882 p=0.032* 

























Table 4. Factorial (two-way) ANOVAs with factors for Treatment (Placebo group, Control group) and 
Diagnosis (fibromyalgia, osteoarthritis, and healthy). 3 ANOVAs were conducted, on Change in 




 Change in 
Expectation 
Change in Anxiety Change in Pain 
Treatment F=17.059; p<0.001** F=0.385; p=0.536 F=31.74; p<0.001** 
Diagnosis F=0.70; p=0.498 F=0.826; p=0.44 F=0.296; p=0.744 
Treatment x Diagnosis F=1.503; p=0.226 F=3.06; p=0.049* F=0.819; p=0.442 


















Table 5. VAS Anxiety levels measured at 5 time-points (Anx1-Anx5) throughout the experiment. 
Osteoarthrosis (OA), fibromyalgia (FM) and healthy (HI) groups.  
 
Anxiety Rating OA  FM HI P value F values df 
Anx1 12.17±15.83 28.481±24.82 12±14.87 p<0.0001*** 19.36 2,30 
Anx2 12.69±12.62 22.86±19.93 12.29±13.03 p<0.0001*** 11.39 2,27 
Anx3 10.19±12.41 24.01±20.90 12.26±12.33 p<0.0001*** 16.69 2,29 
Anx4 9.53±12.34 20.62±19.34 10.38±12.89 p<0.0001*** 12.45 2,29 
Anx5 8.84±16.04 19.05±22.25 9.29±14.1 p=0.0003** 8.24 2,31 
 

















Table 6: Effect of pain reductions during the conditioning phase (“conditioned” in the table) on placebo 
responses. Results are from the linear mixed models 9 to 11 in Supplementary Materials, which 
controlled for pre-conditioned pain ratings and session. Placebo and conditioning changes are site-
specific (i.e. mean pain ratings from the treated arm minus the untreated arm), which also controls for 
habituation effects over time. Beta coefficients are unstandardized and the categorical predictor variable 
(group: placebo vs. control) are dummy coded. 
 
 
Interaction between group and conditioned responses (model 9) 




(Intercept) -0.29 0.10 -2.85 p=0.005* -0.50 -0.09 
conditioned  0.07 0.04 1.74 p=0.082 -0.01 0.15 
treat 0.04 0.12 0.34 p=0.735 -0.20 0.28 
treat:conditioned 0.12 0.05 2.27 p=0.024* 0.02 0.22 
session -0.01 0.07 -0.18 p=0.858 -0.15 0.13 
pre-conditioned 0.74 0.06 13.14 p<0.0001*** 0.63 0.85 
Conditioned responses in the placebo group (model 10) 




(Intercept) -0.27 0.09 -3.05 p=0.0025* -0.44 -0.09 
conditioned 0.20 0.03 5.93 p<0.0001*** 0.13 0.27 
session -0.05 0.09 -0.56 p=0.573 -0.23 0.13 
pre-conditioned 0.64 0.07 8.69 p<0.0001*** 0.49 0.78 
Conditioned responses in the control group (model 11) 




(Intercept) -0.26 0.10 -2.57 p=0.011* -0.47 -0.06 
conditioned 0.05 0.04 1.18 p=0.241 -0.03 0.12 
session 0.03 0.11 0.28 p=0.776 -0.19 0.25 
pre-conditioned 0.94 0.08 11.07 p<0.0001*** 0.77 1.10 
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